Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Clin Cancer Res. 2016 Jun 13;22(19):4901–4912. doi: 10.1158/1078-0432.CCR-15-2242

Figure 6. LEN and commonly used chemotherapy agents enhance EBV reactivation.

Figure 6

(A) Archived serum samples from a trial with myeloma patients receiving THAL and LEN continuously with weekly DEX in a 28-day cycle were evaluated for their EBV viral load by qPCR. EBV viral load copies per ml was calculated for the baseline and first and last cycles of therapy for each patient. “*” denotes p values of <0.01 comparing the final cycle to the baseline viral load. (B) DAUDI cells were treated with LEN, THAL (1µM), or DEX (100 nM), or in two- or three-drug combinations for 48 hours, and cell lysates were immunoblotted with the indicated sera. (C) MUTU-I and DAUDI cells were treated with LEN, MTX, DOX, BZB, MLPH, or RTX alone or in combination with LEN at the indicated concentrations. Protein lysates were immunoblotted with the indicated sera. Representative images are shown from 1 of 3 independent experiments.